Future Science OA (Dec 2024)

A consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study

  • Luu Hong Dang Nguyen,
  • Ba Linh Tieu,
  • Thi Thanh Nguyen,
  • Nhung Phuong Ha,
  • Giang Thi Huong Nguyen,
  • Thi Hue Hanh Nguyen,
  • Van Hoi Le,
  • Vinh Quang Bui,
  • Lan Hieu Nguyen,
  • Nhu Hiep Pham,
  • Thanh Hai Phan,
  • Huu Thinh Nguyen,
  • Van Song Tran,
  • Chi Viet Bui,
  • Van Kha Vo,
  • Pham Thanh Nhan Nguyen,
  • Ha Huu Phuoc Dang,
  • Van Dung Pham,
  • Van Thinh Cao,
  • Ngoc Minh Phan,
  • Van Tung Nguyen,
  • Thi Le Quyen Le,
  • Thi Lan-Anh Luong,
  • Thi Kim Phuong Doan,
  • Canh Duy Phan,
  • Thanh Xuan Nguyen,
  • Nguyen Tuong Pham,
  • Bao Toan Nguyen,
  • Thi Thu Thuy Pham,
  • Huu Linh Le,
  • Cong Thanh Truong,
  • Thanh Xuan Jasmine,
  • Minh Chi Le,
  • Van Bau Phan,
  • Quang Binh Truong,
  • Thi Huong Ly Tran,
  • Minh Thien Huynh,
  • Tu Quy Tran,
  • Si Tuan Nguyen,
  • Vu Tran,
  • Van Khanh Tran,
  • Huu Nguyen Nguyen,
  • Thi Van Phan,
  • Thi Thanh-Thuy Do,
  • Dinh Kiet Truong,
  • Hoa Giang,
  • Hoai-Nghia Nguyen,
  • Minh-Duy Phan,
  • Le Son Tran,
  • Hung Sang Tang,
  • Duy Sinh Nguyen

DOI
https://doi.org/10.1080/20565623.2024.2395244
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

The emergence of multicancer early detection (MCED) tests holds promise for improving early cancer detection and public health outcomes. However, positive MCED test results require confirmation through recommended cancer diagnostic imaging modalities. To address these challenges, we have developed a consultation and work-up protocol for definitive diagnostic results post MCED testing, named SPOT-MAS. Developed through circulating tumor DNA (ctDNA) analysis and in line with professional guidelines and advisory board consensus, this protocol standardizes information to aid general practitioners in accessing, interpreting and managing SPOT-MAS results. Clinical effectiveness is demonstrated through a series of identified cancer cases. Our research indicates that the protocol could empower healthcare professionals to confidently interpret circulating tumor DNA test results for 5 common types of cancer, thereby facilitating the clinical integration of MCED tests.

Keywords